Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck to stop development of hepatitis C treatments

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/29/2017 | 02:22pm CEST

U.S. drugmaker Merck & Co (>> Merck and Company) said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition rises and patient population shrinks.

U.S. drugmaker Merck & Co (>> Merck and Company) said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition rises and patient population shrinks.

The decision was made after reviewing mid-stage trial data of the treatments, said the company, which currently sells hepatitis C drug Zepatier.

Merck is the latest drugmaker to move away from the hepatitis C market.

Earlier this month, Janssen Sciences Ireland UC, a unit of Johnson & Johnson (>> Johnson & Johnson), said it would discontinue further development of its hepatitis C research.

Hepatitis C drugmakers have been struggling with slowing sales growth.

Market leader Gilead Sciences (>> Gilead Sciences) has seen total sales of its hepatitis C drugs - Sovaldi, Harvoni and Epclusa - sharply drop to $2.9 billion (2.17 billion pounds) in the second quarter ended June 30 from $4 billion a year earlier.

Hepatitis C causes inflammation of the liver that can lead to diminished organ function or its failure.

An estimated 2.7 million to 3.9 million people in the United States have chronic hepatitis C infection, according to the Centers for Disease Control and Prevention.

(Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)

Stocks treated in this article : Johnson & Johnson, Gilead Sciences, Merck and Company
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
10/21 MERCK AND : Real-World Study Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted..
10/20DJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
10/20 MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/19 ONCOSEC MEDICAL : Initiates Registration Directed Clinical Trial, KEYNOTE-695, o..
10/19 MERCK FOUNDATION : Launches Five-Year Initiative to Improve Diabetes Care for Vu..
10/19DJMERCK AND : Chenault Among Few Black CEOs -- WSJ
10/19 BERGENBIO : Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB3..
10/18DJMERCK AND : Amex Retirement Shines Light on Lack of Diversity in CEO Ranks
10/18 MERCK AND : U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
10/18 MERCK AND : KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival ..
More news
News from SeekingAlpha
10/21 Stocks to watch next week
10/20 The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
10/20 Merck to lay off 1,800 sales reps
10/20 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 WHY ARE THESE 6 DOW STOCKS FAIRLY VA : Part 4 Of 5
Financials ($)
Sales 2017 40 270 M
EBIT 2017 13 680 M
Net income 2017 5 793 M
Debt 2017 8 103 M
Yield 2017 2,95%
P/E ratio 2017 31,87
P/E ratio 2018 19,03
EV / Sales 2017 4,53x
EV / Sales 2018 4,45x
Capitalization 174 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 9,5%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.88%174 223
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
AMGEN27.41%133 501